Quick Answer
ProMIS Neurosciences Inc. reported Stockholders Equity of -$1.26 million for the year ending 2025.
- ProMIS Neurosciences Inc. showed a decrease of -107.6% in Stockholders Equity from 2024 to 2025.
- This data is from ProMIS Neurosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$6.88 million | Q2 2021: -$7.07 million | Q3 2021: $7.82 million | Q1 2022: $3.74 million | Q2 2022: $6.71 million | Q3 2022: $729.8 thousand | Q1 2023: -$6.18 million | Q2 2023: -$8.53 million | Q3 2023: $6.75 million | Q1 2024: $77.1 thousand | Q2 2024: -$2.28 million | Q3 2024: $7.27 million | Q1 2025: $9.47 million | Q2 2025: -$382.6 thousand | Q3 2025: $9.19 million.
- Over the full 6 years of available data (2020 to 2025), ProMIS Neurosciences Inc.'s Stockholders Equity has declined by 58.0%.
- Historical annual values: Fiscal year 2025: -$1.26 million | Fiscal year 2024: $16.49 million | Fiscal year 2023: $3.75 million | Fiscal year 2022: -$1.35 million | Fiscal year 2021: $5.66 million | Fiscal year 2020: -$796.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: